For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Ovid Therapeutics Inc.

USPTO Granted Patents = 51

CIPO Patents = 4

EPO Patents = 5

Trademarks = 8

Forward Citations = 213

Loading Chart...

Loading Chart...

3 inventors (with patents filed for the assignee):

Matthew J During (51 out of 68 patents)

Anna Kazanchyan (3 out of 6 patents)

Brett Abrahams (3 out of 3 patents)

Core Competencies:

Developmental Disorders

Gaboxadol

Seizure Disorders

Epileptic Disorders

Tourette Syndrome

Prader-Willi Syndrome

Angelman Syndrome

Tinnitus

PDE10A Inhibitors

Behavioral Syndromes

Critical Care Treatment

Attention Deficit Hyperactivity Disorder

51 patents: Sort by Forward Citations

1. 12465597 - Methods of treating developmental disorders with gaboxadol (2025-11-11),

2. 12285397 - Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders (2025-04-29),

3. 12144801 - Methods and compositions for treatment of epileptic disorders (2024-11-19),

4. 12109201 - Methods and compositions for treatment of epileptic disorders (2024-10-08),

5. 11918563 - Methods and compositions for treatment of epileptic disorders (2024-03-05),

6. 11918551 - Methods of treating seizure disorders and Prader-Willi syndrome (2024-03-05),

7. 11903930 - Methods and compositions for treatment of epileptic disorders (2024-02-20),

8. 11806336 - Methods and compositions for treatment of epileptic disorders (2023-11-07),

9. 11771671 - Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction (2023-10-03),

10. 11761006 - Use of MIR101 or MIR128 in the treatment of seizure disorders (2023-09-19),

11. 11690829 - Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder (2023-07-04),

12. 11660277 - Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders (2023-05-30),

13. 11395817 - Methods and compositions for treatment of epileptic disorders (2022-07-26),

14. 11364228 - Gaboxadol for therapeutic treatment of 1p36 deletion syndrome (2022-06-21),

15. 11291658 - Use of gaboxadol in the treatment of diabetes and related conditions (2022-04-05),

Ovid Therapeutics is a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders. They focus on developing treatments for conditions such as Angelman syndrome and Fragile X syndrome, utilizing their expertise in neuroscience and drug development. Ovid Therapeutics strives to improve the well-being of patients and their families by delivering breakthrough therapies and advancing scientific understanding of these conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

51 Patents

#158 in New York, NY

#381 in New York

#6,657 in US

#13,365 in the World

New York, NY, United States of America

Ovid Therapeutics Inc.

Forward Citations = 213

3 inventors:

Matthew J During (51 out of 68 patents)

Anna Kazanchyan (3 out of 6 patents)

Brett Abrahams (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…